Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease

Inclusion Criteria: * Histologically documented unresectable stage III NSCLC. Mediastinal (N2) involvement must be confirmed by biopsy * Stable disease or clinical response after primary therapy of chemo-radiation treatment for unresectable stage III disease * Primary therapy should be a minimum of 2 cycles of Platinum-based first-line chemotherapy, given concurrent with thoracic radiation. The combined modality should consist of either: * induction (2 cycles) chemotherapy followed by concurrent chemo-radiation therapy; or * concurrent chemo-radiation therapy followed by 2 cycles of consolidation chemotherapy; or * concurrent chemoradiation therapy alone * A minimum radiation dose of greater than or equal to (\>=) 6,000 centigray (cGy) should be administered. Subjects must have completed the primary therapy at least 4 weeks and no later than 6 months prior to study entry * Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (\<=) 1 * Ability to understand and willingness to sign a written informed consent * Other protocol defined inclusion criteria could apply Exclusion Criteria: * Undergone lung cancer specific therapy (including surgery) prior to primary chemo-radiation therapy * Received immunotherapy/systemic immunosuppressive drugs/investigational systemic drugs within 4 weeks prior to study entry * Subjects with brain metastases, pleural effusion, unless cytologically confirmed to be non-malignant * Past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years * Autoimmune disease or immunodeficiency * Clinically significant hepatic, renal dysfunction or cardiac diseases * Clinically significant active infection * Pregnant or lactating, women of childbearing potential, unless using effective contraception as determined by the investigator * Other protocol defined inclusion criteria could apply